Cochlear Ltd

Cochlear Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.12 and a current ratio of 2.35, indicating strong short-term liquidity coverage. The balance sheet shows total assets of AUD 2.83 billion against total liabilities of AUD 874.7 million, with long-term debt standing at AUD 235.7 million. Cash and equivalents total AUD 275.7 million, providing a buffer against operational fluctuations. The company generates AUD 237.6 million in operating cash flow, which supports its capital expenditure of AUD 102.6 million, resulting in free cash flow of AUD 98.5 million. This liquidity profile suggests the firm is well-positioned to fund ongoing operations and potential strategic initiatives without immediate refinancing pressure.

Profitability metrics indicate efficient capital utilization, with a return on equity of 19.94% and a return on assets of 13.77%. The company reports a gross profit of AUD 1.73 billion on revenue of AUD 2.34 billion, reflecting a gross margin of approximately 73.7%. Operating income stands at AUD 517.8 million, leading to a net income of AUD 388.9 million. These returns suggest that the company effectively leverages its asset base to generate earnings, although specific comparisons to cohort medians are not available in the provided data to contextualize relative performance within the industry.

Revenue concentration and geographic exposure details are not explicitly provided in the segmented data, limiting the ability to assess specific regional risks or segment-level performance drivers. The total revenue of AUD 2.34 billion represents the consolidated top line, but without breakdowns by product line or geography, the analysis relies on aggregate figures. The absence of segment data prevents a detailed evaluation of revenue mix stability or geographic diversification benefits.

Growth trajectory analysis is constrained by the absence of historical period data in the input. Without five-year annual or eight-quarter quarterly revenue and net income trends, it is not possible to quantify recent growth rates or identify momentum shifts. The current financial snapshot provides a static view of performance, but longitudinal data is required to assess the sustainability of revenue growth and earnings expansion over time.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The company’s low debt levels and strong cash position mitigate financial distress risks. The absence of significant dilution concerns suggests that share count stability is maintained, with basic and diluted shares outstanding both at 65,398,917. This stability supports earnings per share integrity and reduces the risk of value erosion from equity issuance.

Recent events and market sentiment reflect a cautious but positive outlook, with a mean analyst price target of AUD 126.42 and a median target of AUD 125.00. The mean recommendation score of 2.69 indicates a moderate buy stance, with two strong buys, three buys, and ten holds among analysts. The high price target of AUD 170.00 and low target of AUD 95.00 suggest a wide range of expectations, potentially reflecting uncertainty in future growth drivers or regulatory environments. No specific filing, news, or transcript observations are provided to detail recent corporate actions or strategic announcements.

Cochlear generated A$2.34 billion in FY2025 revenue, reflecting an 11.8% compound annual growth rate over the past four years.

Net income grew 9.0% year-over-year to A$388.9 million in FY2025, indicating consistent profitability expansion alongside revenue growth.

The firm maintains a conservative debt-to-equity ratio of 0.12, well below the 0.38 median of its peer cohort.

Cash conversion ratio of 0.61 in FY2025 lagged the 1.19 median of its peer cohort, indicating lower efficiency in converting earnings to cash.

Net income compound annual growth rate was only 4.5% over four years, significantly trailing the 11.8% revenue growth rate.

Analyst consensus recommends a hold rating with a median price target of A$125.0, suggesting limited near-term upside potential.

Revenue A$2.34B, +4,8% YoY; Operating income +9,0% YoY.

• ▍Revenue A$2.34B, +4,8% YoY
• ▍Operating income +9,0% YoY
• ▍Net income +9,0% YoY
• ▍Free cash flow −7,2% YoY
• ▍Net margin 16.6%

Revenue A$2.24B, +15,5% YoY; Operating income +21,9% YoY.

• ▍Revenue A$2.24B, +15,5% YoY
• ▍Operating income +21,9% YoY
• ▍Net income +18,7% YoY
• ▍Free cash flow +20,4% YoY
• ▍Net margin 16.0%

Revenue A$1.94B, +17,5% YoY; Operating income −2,6% YoY.

• ▍Revenue A$1.94B, +17,5% YoY
• ▍Operating income −2,6% YoY
• ▍Net income +4,0% YoY
• ▍Free cash flow −7,3% YoY
• ▍Net margin 15.5%

Revenue A$1.65B, +10,1% YoY; Operating income +6,9% YoY.

• ▍Revenue A$1.65B, +10,1% YoY
• ▍Operating income +6,9% YoY
• ▍Net income −11,4% YoY
• ▍Free cash flow −63,9% YoY
• ▍Net margin 17.5%

Revenue A$1.50B; Operating income A$374.1M.

• ▍Revenue A$1.50B
• ▍Operating income A$374.1M
• ▍Net margin 21.8%